POWERED BY BIOHM

Serial Number 87757230
Registration 6707595
700

Registration Progress

Application Filed
Jan 16, 2018
Under Examination
Feb 19, 2019
Approved for Publication
Dec 25, 2018
Published for Opposition
Dec 25, 2018
Registered
Apr 19, 2022

Basic Information

Serial Number
87757230
Registration Number
6707595
Filing Date
January 16, 2018
Registration Date
April 19, 2022
Published for Opposition
December 25, 2018
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 19, 2022
Registration
Registered
Classes
001 005

Rights Holder

BIOHM HEALTH INC.

99
Address
425 LITERARY ROAD
SUITE 100
CLEVELAND, OH 44113

Ownership History

PathoBiome LLC

Original Applicant
16
Cleveland, OH

PathoBiome LLC

Owner at Publication
16
Cleveland, OH

BIOHM HEALTH LLC

New Owner After Publication #1
16
CLEVELAND, OH

BIOHM HEALTH LLC

Original Registrant
16
CLEVELAND, OH

BIOHM HEALTH INC.

New Owner After Registration #1
99
CLEVELAND, OH

Legal Representation

Attorney
Brian E. Turung
USPTO Deadlines 2 active 2 overdue
Deadline Type Event Code Deadline Date Days Until Priority Extension Available
OPPOSITION
Notice of Publication
NPUB Jan 24, 2019 2356 days overdue Medium Until Feb 24, 2019
ITU SOU
Notice of Allowance Mailed - SOU Required
NOAM Aug 19, 2019 2149 days overdue High Until Feb 19, 2020

Application History

50 events
Date Code Type Description
Feb 15, 2023 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 19, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER
Mar 15, 2022 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 13, 2022 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 1, 2022 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Feb 18, 2022 EISU I TEAS STATEMENT OF USE RECEIVED
Feb 18, 2022 IUAF S USE AMENDMENT FILED
Aug 10, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2021 EX5G S SOU EXTENSION 5 GRANTED
Aug 6, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 28, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 28, 2021 EXT5 S SOU EXTENSION 5 FILED
Feb 17, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 15, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 15, 2021 EXT4 S SOU EXTENSION 4 FILED
Feb 15, 2021 EX4G S SOU EXTENSION 4 GRANTED
Oct 5, 2020 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 5, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 5, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 5, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 5, 2020 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 21, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 19, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 19, 2020 EXT3 S SOU EXTENSION 3 FILED
Aug 19, 2020 EX3G S SOU EXTENSION 3 GRANTED
Feb 28, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 27, 2020 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 27, 2020 EX2G S SOU EXTENSION 2 GRANTED
Feb 18, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 18, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 18, 2020 EXT2 S SOU EXTENSION 2 FILED
Aug 20, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 16, 2019 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 16, 2019 EXT1 S SOU EXTENSION 1 FILED
Aug 16, 2019 EX1G S SOU EXTENSION 1 GRANTED
Feb 19, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 30, 2019 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Dec 25, 2018 PUBO A PUBLISHED FOR OPPOSITION
Dec 25, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 5, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 12, 2018 ALIE A ASSIGNED TO LIE
Oct 28, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 26, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 26, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 26, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 30, 2018 CNRT R NON-FINAL ACTION WRITTEN
Apr 30, 2018 GNRT F NON-FINAL ACTION E-MAILED
Apr 30, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 26, 2018 DOCK D ASSIGNED TO EXAMINER
Jan 29, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Detailed Classifications

Class 001
Food products containing probiotic compositions, namely, probiotic bacteria and probiotic bacterial cultures for use as a food additive for food manufacturing; human food products containing probiotic compositions, namely, probiotic bacteria and probiotic bacterial cultures for use as a food additive for food manufacturing; animal food products containing probiotic compositions, namely, nutritional additives for use in manufacturing animal feed
First Use Anywhere: Feb 17, 2022
First Use in Commerce: Feb 17, 2022
Class 005
Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use, and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; beverages containing probiotic compositions for use as a nutritional supplement; food supplements containing probiotic compositions; human food supplements products containing probiotic compositions; animal food products containing probiotic compositions, namely, probiotic animal feed; dietary supplement drink mixes, namely, probiotic compositions in the form of mixes to added to beverages; dietary supplements in the nature of probiotic compositions for mixing with cereal
First Use Anywhere: Feb 17, 2022
First Use in Commerce: Feb 17, 2022

Classification

International Classes
001 005